Cardiac Contractility Drug Faces Headwinds at FDA Adcomm

(MedPage Today) -- If omecamtiv mecarbil is to gain a heart failure indication, sponsor Cytokinetics has a lot of convincing to do when the FDA Cardiovascular and Renal Drugs Advisory Committee convenes on Tuesday. FDA advisors will spend the...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news